Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DE-122 + ranibizumab
- Development stage
- Unknown
- Lead developer
- Santen Pharmaceutical
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
DE-122 + ranibizumab is a combination therapy under investigation for the treatment of neovascular (wet) age-related macular degeneration (AMD). DE-122 is an ophthalmic formulation of carotuximab, a monoclonal antibody targeting endoglin (CD105), which plays a key role in angiogenesis. Ranibizumab is a recombinant humanized monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A), thereby preventing abnormal blood vessel growth and leakage in the eye. The combination aims to provide dual inhibition of angiogenic pathways—endoglin and VEGF-A—to improve outcomes in patients with wet AMD, particularly those refractory to anti–VEGF monotherapy[1][2][3][4][5][6][8].
- Brand names
- Lucentis
- Other names
- ranibizumabanti-endoglin antibody (for DE-122)VEGF-A inhibitor (for ranibizumab)
02
Targets
VEGFA (Vascular endothelial growth factor A)ENG (Integrin Beta 6)
Beyond the preview
Go deeper on DE-122 + ranibizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DE-122 + ranibizumab.